Valuation conundrum of healthcare-related stocks in US and M’sia


THE United States, which is the epicentre of the Covid-19 pandemic, is the base for some of the world’s largest healthcare companies. These companies are in the race to find a vaccine for the virus and have from time to time disclosed the progress of finding a wonder drug to prevent the spread of the virus.

However, the valuations of the more established pharmaceutical companies have remained sober even though the companies are in the forefront of the search to find a vaccine.

Get 20% OFF The Star Digital Access

Monthly Plan

RM 13.90/month

RM 11.12/month

Billed as RM 11.12 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 9.87/month

Billed as RM 118.40 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

AEON Bank launches new AI-powered interactive app feature
HSBC quarterly profit jumps but shares slide after flat revenue for wealth business
Oil slips 1% as Iran diplomacy eases supply fears
Nestle Malaysia affirms positive outlook for FY26
Matrix Concepts acquires agriculture land in Kulai for RM169.31mil
LPI Capital records 3Q net profit of RM96.82mil
Asian stocks surge as Anthropic IPO lifts sentiment ahead of earnings, central banks
Strengthen energy security, accelerate power grid development - Asean sec-gen
Lufthansa resumes KL-Frankfurt direct flight service
Ringgit opens higher against US$, major currencies

Air Pollutant Index

Note: API is calculated based on 24hr running average of the most dominant parameter.

Highest API Readings

    Select State and Location to view the latest API reading

    Others Also Read